Monthly Archives: April 2009

Good Healthcare Newsmaker in Action: CDC Official Draws on TV Skills for Flu Updates

He has been reassuring. He has explained complicated issues simply. He has even acknowledged not knowing many answers. This is how The New York Times‘ Gardiner Harris described Dr. Richard Besser‘s performance in delivering televised flu updates. Dr. Besser, the acting head of the CDC, has served as the government’s chief health spokesperson on the H1N1 flu outbreak. He attributed his smooth performance to his work as a part-time medical reporter with a San Diego TV station earlier in his career. We, as PR counselors who help scientists, physicians and healthcare executives to master the art of the media interview, praise Dr. Besser for his faithful following of the newsmakers’ and reporters’ bill of rights about which we wrote in an earlier posting.

What are those rights?  Click here to read them and ask yourself whether or not you’re following them in your media relations work.

Renewed Optimism With Capital Markets, Says Deutsche Bank Healthcare VP

There is renewed optimism regarding the capital markets with the IPO market expected to return in 2010, according to Aaron Schwimmer, a vice president in healthcare investment banking with Deutsche Bank Securities. We recently met with Aaron to obtain his outlook on what continues to be a challenging time for emerging healthcare companies.

One point of the discussion was that large pharma companies are interested mainly in companies with unique technologies as takeover candidates.  These technologies include hot areas such as RNAi and those in the more mundane world of high-throughput screening. The companies with early Phase II drugs in development are the most likely targets for acquisition because they are very attractive right now in terms of price. 

In a related area, Aaron expects to see more marketing and distribution agreements concluded between big pharma companies and those with late-stage drugs in the development pipeline.

We’ll stay in close contact with Aaron as our clients evaluate their investment banking needs. Moreover, we look forward to the Deutsche Bank Healthcare Conference next month in Boston.

Corporate Blogs and Tweets: Keep SEC in Mind

http://online.wsj.com/article/SB124078135070257099.html

Corporate blogs and social media tools such as Twitter, Facebook and LinkedIn are becoming more important to our healthcare communications programs — so much that one of our latest offerings is the optimization of company Web sites to enable clients to take incremental steps in this direction without having to dive in head first.  

Published in today’s Wall Street Journal, Cari Tuna’s article speaks to the newfound challenges that are inevitable as we change how we communicate with company stakeholders. The most important takeaway of the article is that companies must establish communications policies that apply to today’s social media tools.

When we kick off PR programs with our clients, one of the first steps involves the establishment of protocols and policies that apply to all internal and external communications. The impact of social media because of its immediacy alone is enough to warrant a review of a company’s current communications policy.

Does your company’s communications policy cover social media?  We suggest that you take a look.

Participating in “The Twitter Revolution”

http://budurl.com/nd3l

As published in the weekend edition of The Wall Street Journal, “The Twitter Revolution” lays out the story of the fastest-growing social networking tool. As healthcare PR counselors, we’ve adopted Twitter as another distribution channel for agency and client news. This means that in addition to distributing news release about a biopharmaceutical company’s clinical trial data via PR Newswire and e-mail, we send it embedded in a Twitter “tweet” to our followers: journalists, healthcare execs and others.  We expect Twitter to gain in importance in our toolkit as more members of our publics embrace it for its simplicity and speed.  To follow our news on Twitter, go to www.twitter.com/russopartners.

Evaluating Your Performance as a Newsmaker

When Russo Partners’ clients “meet the press,” we counsel them to evaluate their interview performances by:

1. Determining whether or not they get their “must air” points, or key messages, into the articles or broadcast segments

We should be able to highlight the points that we developed in our interview prep sessions.

2. Asking whether or not they anticipated and effectively handled the tough questions

A good interview is a natural discussion. We never script spokespersons. Our interview prep sessions involve our identification of the difficult questions the clients could receive as well as our development of points to satisfy the questions.

3. Measuring the clients’ credibility

We counsel clients to satsify all relevant questions before steering to the “must air” points. This is in contrast to to the interview style of many politicians who typically steer to their own points without answering questions.  Our clients can’t afford to damage their credibility as newsmakers for their companies.

A recent example of this approach to evaluating media interview performance involved John Babich, the president, CEO and CSO of Cambridge, Mass.-based Molecular Insight Pharmaceuticals.  In conjunction with the company’s announcement of Phase II study data for lead compound Zemiva, we prepped John for a telephone interview with Peter Benesh, who covers biotechnology for Investor’s Business Daily. We worked with John to develop three points about the challenges doctors face when evaluating patients who arrive in the ER with chest pain, the solution that Zemiva offers along with the clinical validation, and information about the company’s other compounds.

The article that resulted from this interview was a homerun.  Two of John’s “must air” points were featured prominently in his own words. Moreover, John handled the difficult questions with ease in the interview.  Peter thanked John for his work and agreed to call on him for future articles. This signalled Peter’s recognition of John as a credible newsmaker.

Your Science or Technology is on the Cutting Edge. Are Your People?

As The Leadership Edge writes on its Web site, great science or technology alone doesn’t make a great company. To turn an innovative concept into a business reality, emerging healthcare companies need leadership and commercial competence.

This is where La Jolla, Calif.-based The Leadership Edge makes its mark. For 20 years, the firm has provided training and consulting services almost exclusively to life sciences and technology companies. The Leadership Edge’s client roster is a who’s who of industry movers and shakers nationwide, including Anadys Pharmaceuticals, Exelixis and Roche Pharmaceuticals.

Russo Partners is pleased to introduce an alliance with The Leadership Edge to bring the award-winning services to current and prospective clients.  While our own training services focus on preparing executives for communications purposes, including presentations and media interviews, The Leadership Edge’s services will serve as a nice complement to round out our offerings.

To learn more about The Leadership Edge, contact Gaylene Xanthopoulos at gaylene@theleadershipedge.com.

March Wrap-Up: Clinical Data Presentations Take Center Stage

March was a big month for multiple Russo Partners clients in  terms of clinical trial data presentations and announcements. Specifically:

Calixa Therapeutics, a San Diego start-up under the watch of investor Domain Associates and antibiotic development expert Dr. James Ge, reported positive Phase I results for a novel intravenous cephalosporin. The key to this compound is its performance against Pseudomonas aeruginosa, which causes nasty infections and for which there is nothing today in drug companies’ pipelines. Calixa’s plans call for the quick entry into the clinic in a Phase II study of the compound.

Corthera, a San Mateo, Calif., company also backed by Domain Associates , enjoyed a strong showing at the American College of Cardiology’s Annual Scientific Session with the presentation of Phase II data for relaxin, which the company is developing for the treatment of acute heart failure. The study’s principal investigator, Dr. John Teerlink, presented the data on the main stage of the conference as part of a late-breaker abstract session. Not only did the promising data turn heads of the several hundred heart failure specialists in attendance, it caught the eye of Forbes‘ Matt Herper, who included relaxin and its interesting premise in a conference round-up.

Rounding out the m0nth, Cambridge, Mass.-based Molecular Insight Pharmaceuticalsannounced its complete data set for the Phase II study of radiopharmaceutical imaging agent Zemiva. The impressive results demonstrated the ability of Zemiva imaging, when combined with the initial clinical information obtained in emergency department assessments of patients, greatly improved sensitivity of detection compared to the assessments alone. Zemiva’s study results were captured in several articles by prominent news outlets, including Reuters.

The second quarter, with its full slate of medical conferences, is expected to be an active one in terms of additional clinical trial data presentations for Russo Partners’ clients. We’ll capture the findings in future posts.